|Advances in flow cytometry could enable researchers to uncover valuable insights about food allergies without allergen exposure.Food allergies affect an estimated 220 million people(Opens in a new window) around the world, the World Health Organization reports. In the United States alone, one in 13 children are living with life-threatening food allergies, according to the non-profit organization Food Allergy Research and Education (FARE(Opens in a new window)). A major milestone in this field was reached in 2024 when the U.S. Food and Drug Administration approved the first biologic to treat food allergies after accidental exposures, Xolair (omalizumab). While there are a handful of other food-allergy treatments in the development pipeline, including combinations of monoclonal antibodies and immune-boosting drugs, innovation in this field remains limited. Replacing dated and harmful methods One limitation holding back the development of new therapies for food allergies is that many commonly used research tools are outdated and ...
Recently, the leading player in the pharmaceutical retail industry, Dachanlin (603233. SH), held a performance briefing for 2024 and the first quarter of 2025, showcasing the company’s operating results and future development plans in all aspects. Peng Guangzhi, the Chief Financial Officer and Secretary of the Board of Directors of the company, pointed out that Da Canlin has successfully built a store network covering 21 provinces (autonomous regions, municipalities directly under the central government) across the country, and the cross provincial expansion battle has been basically completed. In 2025, the company will focus on accelerating the increase of market share in areas already covered by encryption and further strengthen economies of scale. In 2024, Da Canlin submitted a remarkable report card. In 2024, the company achieved a revenue of approximately 26.497 billion yuan, a net profit attributable to shareholders of the listed company of approximately 915 million yuan, a net ...
Today (June 16th), Shanghai Aike Baifa Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Aike Baifa”) announced that its new drug Aizhida (generic name: Sildenafil/Dexmedetomidine Compound Capsules; code: AK0901) has been officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) of China, and has been included in the “priority review and approval” procedure. The proposed indication is the treatment of attention deficit hyperactivity disorder (ADHD) patients aged 6 years and above. Attention Deficit Hyperactivity Disorder (ADHD), commonly known as ADHD, is a chronic brain disease characterized by difficulty concentrating, hyperactivity, and impulsivity. ADHD symptoms may begin to appear in children between the ages of 3-6 and can persist into adolescence and adulthood. ADHD is the most common mental illness in childhood, affecting 8% to 9% of school-age children. Methylpheniramate has been recommended as a first-line treatment option for children and adults with ADHD in ...
Heyu announced on the Hong Kong Stock Exchange that its subsidiary Shanghai Heyu Biopharmaceutical Technology Co., Ltd. (“Heyu Pharmaceutical”) has completed the first patient dosing in the registration clinical trial of its independently developed highly selective small molecule FGFR4 inhibitor ipagotinib for the treatment of hepatocellular carcinoma (HCC). Ipagotinib was recognized as a breakthrough therapy by the Drug Evaluation Center of the China National Medical Products Administration in May 2025. Ipagotinib is also the first drug to use targeted molecular biomarkers to precisely treat HCC. https://finance.eastmoney.com/a/202506163430938887.html
June 15, Huahai Pharmaceutical(600521.SH) announced that the company recently received the “Drug Registration Certificate” for Quetiapine Fumarate Sustained-Release Tablets approved and issued by the State Drug Administration. The drug is used to treat depressive episodes of schizophrenia and bipolar disorder. It was first developed by AstraZeneca and launched in the United States in 2007. According to the data of Minnet, the domestic market sales amount in 2024 will be about 451 million yuan. Huahai Pharmaceutical has invested about 16.93 million yuan in research and development expenses in this project. The approval of this drug further enriches the company’s product line, enhances market competitiveness, and has a positive effect on business development. https://finance.eastmoney.com/a/202506153430842883.html
Recently, the first prescription of Amytosai injection, the first stem cell drug approved for marketing in China, was issued at Peking University People’s Hospital for the treatment of haploid transplant patients. The drug costs 19,800 yuan per treatment, and the total cost is about 158,000 yuan if 8 treatments are considered a complete course of treatment. In comparison with the international market, the U.S. FDA-approved mesenchymal stem cell drug Ryoncil is priced at as high as US$194,000 (about RMB 1.39 million) per dose, which is 70 times the cost of a single dose of Aimitocel injection. The first approved The stem cell therapy Amymatosai Injection (trade name: Ruibosheng) developed by Beijing Bosheng Excellence Biotechnology Co., Ltd. was conditionally approved for marketing by the National Medical Products Administration through the priority review and approval procedure on January 2, 2025. It is indicated for the treatment of acute graft-versus-host disease (aGVHD) in ...
Recently, the State Intellectual Property Office announced the awarding decision of the 25th China Patent Award. HEC Pharmaceutical’s invention patent “Oseltamivir Phosphate Granules and Preparation Method thereof” (patent number ZL200610066995.7) won the 25th China Patent Gold Award. The China Patent Award is jointly sponsored by the State Intellectual Property Office and the World Intellectual Property Organization. It has nine awards, including the China Patent Gold Award, the China Design Gold Award, and the China Patent Award Best Organization Award. Among them, the gold award project must have a significant level of innovation, outstanding market value and extensive social influence, representing the highest honor in China’s intellectual property field. The award of the invention patent “Oseltamivir Phosphate Granules and Preparation Methods” of East Sunshine Pharmaceutical not only demonstrates the company’s innovative strength in the pharmaceutical field, but also confirms the product’s outstanding performance in terms of technological innovation, clinical value, and ...
Kelun PharmaceuticalIt was disclosed on the evening of June 12 that the chemical drug “Cefazolin Sodium/Sodium Chloride Injection for Injection” of the company’s subsidiary Hunan Kelun Pharmaceutical Co., Ltd. recently obtained drug registration approval from the State Food and Drug Administration. Disclosures show that cefazolin sodium is a classic drug for anti-infective treatment. It is currently widely used in clinical practice for various perioperative preventive medications and treatment of respiratory tract, skin and soft tissue, bone and joint infections caused by sensitive bacteria. It is also the only cephalosporin recognized by WHO as the preferred choice for surgical prevention. Cefazolin Sodium/Sodium Chloride Injection for Injection is a Class B national medical insurance product. In 2024, sales of cefazolin sodium injection in China will reach 1.35 billion yuan. The Cefazolin Sodium/Sodium Chloride Injection for Injection for which Kelun Pharmaceutical has obtained a drug registration certificate is a powder-liquid double-chamber bag, with ...
June 12, Hybio Pharmaceutical released the record of investor relations activities. HY3003 is a GLP-1R/GIPR/GCGR triple-target receptor agonist screened by Hanyu Pharmaceuticals and its partners using AI peptide chip technology for weight loss indications. As of this week, the preclinical optimal candidate compound screening and API process development have been completed, and the API pilot scale-up stage has officially begun. In addition to triple-target weight loss drugs, the company also has 1.1-class innovative drugs. HY3000 nasal spray, which is indicated for the prevention of coronavirus infection, is currently in the phase III clinical trial stage. In terms of the exploration of innovative cannabidiol (CBD) drugs , the company has established a partnership with Sinopharm In-depth cooperation is carried out in the fields of research and development of innovative cannabidiol (CBD) drugs , integration of peptide and small nucleic acid drug technologies, and commercial promotion. In terms of clinical progress, the ...
On June 12, Sailon (002898) announced that its wholly-owned subsidiary Hunan Sailon Pharmaceutical (Changsha) Co., Ltd. recently obtained the Drug Registration Certificate for Famotidine Injection approved and issued by the State Drug Administration. The drug is a Class 3 chemical drug, with an injection form and specifications of 1ml: 10mg and 2ml: 20mg. The registration certificate number is 2025S01758/2025S01757, and it is valid until June 9, 2030. Famotidine injection is listed as a national basic medical insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2024)” Class A drugs, mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer. The approval of the drug will further enrich the company’s preparation varieties, but the specific sales situation is still affected by a variety of internal and external environmental factors, and there is a certain degree of uncertainty. In the first quarter of 2025, Sailon achieved revenue of 54.09 million yuan ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.